* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
AMM:DADI's PEG Ratio is ranked worse than 95.42% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.69
vs AMM:DADI: 24.50
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Dar Al Dawa Development and Investment (AMM:DADI) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Dar Al Dawa Development and Investment PEG Ratio Related Terms
Dar Al Dawa Development and Investment PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment PEG Ratio Chart
Dar Al Dawa Development and Investment Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment PEG Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Dar Al Dawa Development and Investment (AMM:DADI) has a PEG Ratio of 24.52 as of Jul. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 734% above median its historical median of 2.94. Over the past decade, Dar Al Dawa Development and Investment's PEG Ratio has ranged from 2.87 to 24.50. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #333 out of 349 companies in the Drug Manufacturers industry, placing it in the top 95.4%.
Is Dar Al Dawa Development and Investment's PEG Ratio too high?
Dar Al Dawa Development and Investment's current PEG Ratio of 24.52 is 734% above median its 10-year median of 2.94. Over the past 10 years, this metric has ranged from a low of 2.87 to a high of 24.50. The Drug Manufacturers industry median PEG Ratio is 1.69. Dar Al Dawa Development and Investment's value of 24.52 is 1350.9% above this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #333 out of 349 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #333 out of 349 companies for PEG Ratio. This places Dar Al Dawa Development and Investment in the lower half of its industry. The industry median PEG Ratio is 1.69. Dar Al Dawa Development and Investment's value of 24.52 is 1350.9% above this benchmark. Historically, Dar Al Dawa Development and Investment's own PEG Ratio has ranged from 2.87 to 24.50 over the past decade. While the company's 10-year median is 2.94 vs. the industry median of 1.69, Dar Al Dawa Development and Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.69, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current PEG Ratio of 24.52 is 1350.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current PEG Ratio is 24.52, which is 734% above median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.10, compared to a current price of JOD1.14 — trading 3.6% above its estimated fair value. The current PEG Ratio is 24.52, which is 734% above median its 10-year median of 2.94 and 1350.9% above the Drug Manufacturers industry median of 1.69. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current PEG Ratio is 24.52 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.14 is trading 3.6% above its estimated GF Value™ of JOD1.10.
GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.
Key valuation signals for AMM:DADI:
PEG Ratio: 24.52 (734% above median its 10-year median of 2.94)
GF Value™: JOD1.10 vs. price of JOD1.14 (3.6% above fair value)
Industry Position: 1350.9% above the Drug Manufacturers median (#333 of 349)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment Business Description
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score
Get the complete analysis for AMM:DADI
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
